|By PR Newswire||
|March 24, 2014 11:59 PM EDT||
DUBLIN, March 25, 2014 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/llq9cw/investigation) has announced the addition of the "Investigation Report on China Bevacizumab Market, 2009-2018" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
Bevacizumab is an important kind of remedy for metastatic colon cancer, which belongs to humanized anti-VEGF monoclonal antibody. Approved by FDA, bevacizumab came into the market in 2004, with the brand name of ""Avastin"". Its main mechanism is to inhibit the function of a natural protein called vascular endothelial growth factor (VEGF) that stimulates new blood vessel formation through specific binding so as to stop or delay growth of blood vessels in tumor, disconnect the delivery of oxygen and other nutrition necessary in tumor cells' growth, as well as to improve the effect of chemotherapy remedy. Public data shows that the global sales value of bevacizumab in 2012 exceeded USD 6.3 billion, ranking the fourth among the 10 best selling monoclonal antibody drugs.
As Chinese economy develops rapidly, Chinese people's lifestyle is changing tremendously. With the aging level increasing, environment pollution worsening, the incidence of cancer in China keeps rising. Statistics indicate that the annual increase of cancer patients in China takes up over 20% of the global, making China a capital antitumor remedy market of the world. Shanghai Roche Pharmaceuticals Ltd. declared on May 7, 2010 that its bevacizumab injection (brand name ""Avastin"") was approved by the FDA for curing metastatic colorectal cancer. It is the official entry of the world's first angiogenesis inhibitor into Chinese market. The market investigation of CRI manifests that the sales value of Avastin in certain Chinese sample hospitals in 2010 was merely CNY 10 million, growing rapidly. It broke through CNY 200 million in 2013.
There have been some generic drug manufacturers developing bevacizumab around the world. At the end of 2013, Huahai Pharmaceutical in China announced that its bevacizumab generic drug developed with Oncobiologics Company was approved to conduct the first clinical trial in the European Union.
Some study declared that the combination of bevacizumab and chemotherapy can prolong overall survival time of advanced cervical cancer patients. This result indicates the possibility of this remedy with the annual sales value of USD 1 billion to treat cervical cancer.
Key Topics Covered:
1 Relevant Concepts of Bevacizumab
2 Market Overview of Bevacizumab in China, 2010-2013
3 Investigation on Sales Value of Bevacizumab in China, 2010-2013
4 Investigation on Market Share of Major Bevacizumab Manufacturers in China, 2010-2013
5 Investigation on Market Size of Bevacizumab by Dosage Form in China, 2010-2013
6 Reference Price of Bevacizumab in Hospital Market in China, 2010-2013
7 Prospect of China Bevacizumab Market, 2014-2018
- Shanghai Roche Pharmaceuticals Ltd.
For more information visit http://www.researchandmarkets.com/research/llq9cw/investigation
Media Contact: Laura Wood , +353-1-481-1716, [email protected]
SOURCE Research and Markets
Aug. 24, 2016 12:00 PM EDT Reads: 3,810
Aug. 24, 2016 11:45 AM EDT Reads: 1,418
Aug. 24, 2016 11:45 AM EDT Reads: 3,337
Aug. 24, 2016 11:00 AM EDT Reads: 366
Aug. 24, 2016 11:00 AM EDT Reads: 2,064
Aug. 24, 2016 10:48 AM EDT Reads: 247
Aug. 24, 2016 10:45 AM EDT Reads: 1,782
Aug. 24, 2016 10:30 AM EDT Reads: 436
Aug. 24, 2016 10:19 AM EDT Reads: 254
Aug. 24, 2016 10:00 AM EDT Reads: 423
Aug. 24, 2016 09:45 AM EDT Reads: 2,238
Aug. 24, 2016 09:45 AM EDT Reads: 429
Aug. 24, 2016 09:36 AM EDT Reads: 201
Internet of @ThingsExpo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 19th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The Internet of Things (IoT) is the most profound change in personal and enterprise IT since the creation of the Worldwide Web more than 20 years ago. All major researchers estimate there will be tens of billions devices - comp...
Aug. 24, 2016 09:00 AM EDT Reads: 3,492
SYS-CON Events announced today that StarNet Communications will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. StarNet Communications’ FastX is the industry first cloud-based remote X Windows emulator. Using standard Web browsers (FireFox, Chrome, Safari, etc.) users from around the world gain highly secure access to applications and data hosted on Linux-based servers in a central data center. ...
Aug. 24, 2016 08:59 AM EDT Reads: 321